Illumina Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2018
January 29, 2019 at 04:05 pm
Share
Illumina Inc. announced earnings results for the fourth quarter ended December 30, 2018. For the fourth quarter, the company announced total revenue was USD 867 million compared to USD 778 million a year ago. Operating income was USD 197 million compared to USD 230 million a year ago. Net income was USD 210 million compared to USD 68 million a year ago. Basic earnings per share was USD 1.43 compared to USD 0.47 a year ago. Diluted earnings per share was USD 1.41 compared to USD 0.46 a year ago. For the full year, total revenue was USD 3,333 million compared to USD 2,752 million a year ago. Operating income was USD 883 million compared to USD 606 million a year ago. Net income was USD 826 million compared to USD 726 million a year ago. Basic earnings per share was USD 5.63 compared to USD 4.96 a year ago. Diluted earnings per share was USD 5.56 compared to USD 4.92 a year ago.
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
ILLUMINA, INC. 
